Leonardo Biosystems

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

People in the News

Premium

Arrowhead Research has appointed Bruce Given as its COO.

People in the News

Premium

Mauro Ferrari

Leonardo, which had been expecting the funding, intends to use the money to ramp up its operations with the goal of securing industry partnerships around its so-called multi-stage delivery approach.

While the company may at some point down the road dip its toes into the drug-development waters, "initially, I don't see us having any in-house discovery efforts," Leonardo CEO Bruce Given said.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.